key: cord-0819290-m1t9pg6v authors: Tian, Yuan; Rong, Long title: Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with coronavirus disease 2019—authors' reply date: 2020-08-14 journal: Aliment Pharmacol Ther DOI: 10.1111/apt.15986 sha: 7548ff24df48d030056bbb9cda6c758a59643a06 doc_id: 819290 cord_uid: m1t9pg6v LINKED CONTENT This article is linked to Tian et al and Ianiro et al papers. To view these articles, visit https://doi.org/10.1111/apt.15731 and https://doi.org/10.1111/apt.15946 We have read with great interest the article by Ianiro et al describing a prospective cross-sectional study of gastrointestinal (GI) symptoms in Western patients with COVID-19. 1 Comparing Eastern data obtained during the early stage of the pandemic and Western data gained at the later stage, some studies showed that the prevalence of GI symptoms in Western patients was higher than that in Eastern patients. 2 We speculate that this may be related to different strains of SARS-CoV-2. The main virus spreading in Europe is a Spike G614 mutant, and patients infected by it have higher viral loads than those carrying D614 virus in China. 3 Besides, the S protein present in the G614 mutant binds more readily to the ACE2 receptor. 4 A growing number of studies suggested that critically ill patients were more likely to have GI manifestations. 5 A meta-analysis of 6686 patients showed that the incidence of GI symptoms in patients with severe COVID-19 was higher than in patients with non-severe disease (OR: 1.6, 95% CI: 1.09-2.36, P = 0.002). 6 GI symptoms might be a predictor of the critical clinical features mentioned by Dr Ianiro. 1 However, we are curious about which traits are more indicative of possible severe illness in their study. Abdominal pain was more likely to be observed in patients with severe disease (OR:7.1, 95%CI: 1.93-26.07, P = 0.010), but there was no significant difference in the loss of appetite, diarrhoea, nausea and vomiting between patients with severe and mild COVID-19. 6 We speculate that abdominal pain might be more specific than other GI symptoms in critical cases. One possible reason is that, compared to diarrhoea or nausea and vomiting, abdominal pain is a less common adverse effect caused by currently used COVID-19 therapies. 2 They also concluded that the mortality among patients with COVID-19related intestinal ischaemia was 1.7-times higher (95%CI: 0.3-9.6) than that before the COVID-19 pandemic. However, severely ill patients with abdominal pain were rare, so no conclusion could be drawn. Although the majority of GI symptoms were mild and selflimiting, we should still be vigilant as some GI symptoms may indicate a poor prognosis. The authors' declarations of personal and financial interests are unchanged from those in the original article. 9 Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with coronavirus disease 2019 AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19 Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types AP&T correspondence columns are restricted to letters discussing papers that have been published in the journal. A letter must have a maximum of 500 words, may contain one table or figure, and should have no more than 10 references Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Endothelial cell infection and endotheliitis in COVID-19 Poor outcome of intestinal ischemic manifestations of COVID 19 Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission